CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Orgovyx relugolix Advanced prostate cancer Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Active
Repatha evolocumab Primary hyperlipidemia Active
Keytruda pembrolizumab Biliary tract carcinoma Active
Tagrisso osimertinib Non-small cell lung cancer Active
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
N/A mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
Vraylar cariprazine Schizophrenia Active
N/A Nab-paclitaxel Gastrointestinal cancer Active
Qulipta atogepant Migraine, prevention Active
Last Updated : May 9, 2024